Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-906-2 | CAS number: 22450-96-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute toxicity oral: LD50 > 2000 mg/kg bodyweight (OECD 423)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- April to May 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP Guideline (OECD 423) compliant study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd.
- Age at study initiation: 8-9 weeks
- Weight at study initiation: 230-270 g
- Fasting period before study: Overnight prior to dosing and approximately four hours after dosing
- Housing: The cages were solid bottomed polycarbonate cages with a stainless steel mesh lid. Each cage contained a quantity of autoclaved softwood bark-free fibre bedding. Cages, food hoppers, water bottles and bedding were changed at appropriate intervals.
- Diet (e.g. ad libitum): Rat and Mouse No. 1 Maintenance Diet was available ad libitum, with the exception stated above
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 12 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): target 19-23°C
- Humidity (%): 40 to 70%
- Air changes (per hr): not reported, however periodic checks performed
- Photoperiod (hrs dark / hrs light): 12 h light/12 h dark
IN-LIFE DATES: From: 09 April 2013 To: 03 May 2013 - Route of administration:
- oral: gavage
- Vehicle:
- other: 1% methylcellulose
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 30 and 200 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg
- Justification for choice of vehicle: A vehicle trial performed in 1% methylcellulose resulted in a white suspension that was suitable for dosing.
MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: The dose levels for the study were chosen in compliance with the study guidelines. As no previous toxicological information was available the initial dose was 300 mg/kg. - Doses:
- 300 and 2000 mg/kg
- No. of animals per sex per dose:
- 2 groups of 3 females at each dose level (animals R1-R3 and R4-R6 at 300 mg/kg and R7-R9 and R10-R12 at 2000 mg/kg)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observations twice daily and body weights weekly or at death
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs - Preliminary study:
- Not applicable
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 - <= 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- One female (R9) dosed at 2000 mg/kg died on Day 1. Clinical signs prior to death comprised fast breathing, flat posture, tremors, convulsion, partially or fully closed eyelids, irregular breathing, underactive behaviour, hindlimbs splayed, increased body tone, shallow breathing, salivation and reduced body temperature. These signs were seen from approximately 20 minutes after dosing. A loss in bodyweight was noted for the decedent. Macroscopic examination of the animal revealed congestion (characterised by darkened tissues/organs) of the subcutaneous tissue, liver and small and large intestines, pallor of the lungs and white liquid fluid contents in the stomach.
One female (R10) dosed at 2000 mg/kg died on Day 2. Clinical signs prior to death comprised fast breathing, hunched posture, tremors, piloerection, partially closed eyelids, irregular breathing, underactive behaviour, reduced body tone, flat posture, salivation and reduced body temperature. These signs were seen from approximately 20 minutes after dosing. A loss in bodyweight was noted for the decedent. Macroscopic examination of the animal revealed congestion (characterised by darkened tissues/organs) of the subcutaneous tissue, lungs and small and large intestines, a small caecum and dark red liquid fluid contents in the small intestines and yellow liquid fluid content in the large intestines. - Clinical signs:
- other: Clinical signs of reaction to treatment comprised fast breathing, tremors, piloerection, hunched posture and unsteady gait seen in all females dosed at 2000 mg/kg. Underactive behaviour, irregular breathing, and reduced body temperature were seen in three
- Gross pathology:
- Macroscopic examination at study termination on Day 15 revealed a small stomach for one female (R8) treated at 2000 mg/kg. No abnormalities were revealed in any other animal at the macroscopic examination at this time.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute median lethal oral dose (LD50) to rats of SABoTBA was demonstrated to be between 2000 and 5000 mg/kg bodyweight.
- Executive summary:
The study was performed to assess the acute oral toxicity of SABoTBA to the rat using the acute toxic class method (OECD Guideline 423). Two groups of three fasted female rats received a single oral gavage dose of the test substance, formulated in 1% methylcellulose, at a dose level of 300 mg/kg bodyweight. As results at this dose level indicated the acute (median) lethal oral dose of the test substance to be greater than 300 mg/kg bodyweight, in compliance with the study guidelines a further two groups of three fasted females were similarly dosed at 2000 mg/kg bodyweight to complete the study.
One female dosed at 2000 mg/kg died on Day 1. Clinical signs prior to death comprised fast breathing, flat posture, tremors, convulsion, partially or fully closed eyelids, irregular breathing, underactive behaviour, hindlimbs splayed, increased body tone, shallow breathing, salivation and reduced body temperature. These signs were seen from approximately 20 minutes after dosing. A loss in bodyweight was noted for the decedent. Macroscopic examination of the animal revealed congestion (characterised by darkened tissues/organs) of the subcutaneous tissue, liver and small and large intestines, pallor of the lungs and white liquid fluid contents in the stomach. One female dosed at 2000 mg/kg died on Day 2. Clinical signs prior to death comprised fast breathing, hunched posture, tremors, piloerection, partially closed eyelids, irregular breathing, underactive behaviour, reduced body tone, flat posture, salivation and reduced body temperature. These signs were seen from approximately 20 minutes after dosing. A loss in bodyweight was noted for the decedent. Macroscopic examination of the animal revealed congestion (characterised by darkened tissues/organs) of the subcutaneous tissue, lungs and small and large intestines, a small caecum and dark red liquid fluid contents in the small intestines and yellow liquid fluid content in the large intestines. Clinical signs of reaction to treatment in surviving animals comprised fast breathing, tremors, piloerection, hunched posture and unsteady gait seen in all females dosed at 2000 mg/kg. Underactive behaviour, irregular breathing, and reduced body temperature were seen in three females dosed at 2000 mg/kg. Partially closed eyelids, reduced body tone, flat posture and thin build were seen in two females dosed at 2000 mg/kg and lachrymation, brown staining on the head, convulsion and increased body tone were observed for individual animals dosed at 2000 mg/kg. These signs were first noted approximately 20 minutes after dosing. Recovery of surviving animals, as judged by external appearance and behaviour, was complete by Day 10. No clinical signs were seen in any animal dosed at 300 mg/kg. A low bodyweight gain was noted for two females receiving 300 mg/kg and two females receiving 2000 mg/kg on Day 15 and a bodyweight loss was recorded for one female receiving 300 mg/kg on Day 15. All other surviving animals were considered to have achieved satisfactory bodyweight gains throughout the study. Macroscopic examination at study termination on Day 15 revealed a small stomach for one female treated at 2000 mg/kg. No abnormalities were revealed in any other animal at the macroscopic examination at this time.
The acute median lethal oral dose (LD50) to rats of SABoTBA was demonstrated to be between 2000 and 5000 mg/kg bodyweight.
Reference
Table 1 Mortality Data
Dose (mg/kg) |
No. of deaths in groups of 3 |
Day |
|||||
1 |
2 |
3 to 15 |
|||||
<5m |
ca 4.5 h |
a |
b |
a |
b |
||
300 |
0/3F |
- |
- |
- |
- |
- |
- |
300 |
0/3F |
- |
- |
- |
- |
- |
- |
2000 |
1/3F |
0 |
1 |
0 |
0 |
0 |
0 |
2000 |
1/3F |
0 |
0 |
1 |
0 |
0 |
0 |
a = first observation, b = second observation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
The study was performed to assess the acute oral toxicity of SABoTBA to the rat using the acute toxic class method (OECD Guideline 423). Two groups of three fasted female rats received a single oral gavage dose of the test substance, formulated in 1% methylcellulose, at a dose level of 300 mg/kg bodyweight. As results at this dose level indicated the acute (median) lethal oral dose of the test substance to be greater than 300 mg/kg bodyweight, in compliance with the study guidelines a further two groups of three fasted females were similarly dosed at 2000 mg/kg bodyweight to complete the study.
One female dosed at 2000 mg/kg died on Day 1. Clinical signs prior to death comprised fast breathing, flat posture, tremors, convulsion, partially or fully closed eyelids, irregular breathing, underactive behaviour, hindlimbs splayed, increased body tone, shallow breathing, salivation and reduced body temperature. These signs were seen from approximately 20 minutes after dosing. A loss in bodyweight was noted for the decedent. Macroscopic examination of the animal revealed congestion (characterised by darkened tissues/organs) of the subcutaneous tissue, liver and small and large intestines, pallor of the lungs and white liquid fluid contents in the stomach. One female dosed at 2000 mg/kg died on Day 2. Clinical signs prior to death comprised fast breathing, hunched posture, tremors, piloerection, partially closed eyelids, irregular breathing, underactive behaviour, reduced body tone, flat posture, salivation and reduced body temperature. These signs were seen from approximately 20 minutes after dosing. A loss in bodyweight was noted for the decedent. Macroscopic examination of the animal revealed congestion (characterised by darkened tissues/organs) of the subcutaneous tissue, lungs and small and large intestines, a small caecum and dark red liquid fluid contents in the small intestines and yellow liquid fluid content in the large intestines. Clinical signs of reaction to treatment in surviving animals comprised fast breathing, tremors, piloerection, hunched posture and unsteady gait seen in all females dosed at 2000 mg/kg. Underactive behaviour, irregular breathing, and reduced body temperature were seen in three females dosed at 2000 mg/kg. Partially closed eyelids, reduced body tone, flat posture and thin build were seen in two females dosed at 2000 mg/kg and lachrymation, brown staining on the head, convulsion and increased body tone were observed for individual animals dosed at 2000 mg/kg. These signs were first noted approximately 20 minutes after dosing. Recovery of surviving animals, as judged by external appearance and behaviour, was complete by Day 10. No clinical signs were seen in any animal dosed at 300 mg/kg. A low bodyweight gain was noted for two females receiving 300 mg/kg and two females receiving 2000 mg/kg on Day 15 and a bodyweight loss was recorded for one female receiving 300 mg/kg on Day 15. All other surviving animals were considered to have achieved satisfactory bodyweight gains throughout the study. Macroscopic examination at study termination on Day 15 revealed a small stomach for one female treated at 2000 mg/kg. No abnormalities were revealed in any other animal at the macroscopic examination at this time.
The acute median lethal oral dose (LD50) to rats of SABoTBA was demonstrated to be between 2000 and 5000 mg/kg bodyweight.
Justification for selection of acute toxicity – oral endpoint
Key study, GLP/Guideline compliant
Justification for classification or non-classification
Acute oral toxicity
In accordance with EU CLP (Regulation (EC) No. 1272/2008), classification is not required for acute oral toxicity based on the available data.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.